Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL246816 | 0.89 | — | — | |
| SCHEMBL15263448 | 0.89 | SLC1A3 (0.32) | — | |
| Phosphonic Acid SCHEMBL29068484 | 0.79 | — | — | |
| SCHEMBL29052711 | 0.69 | TDP1 (0.33) | — | |
| SCHEMBL672200 | 0.69 | SLC1A3 (0.30) | — | |
| SCHEMBL8565780 | 0.69 | SMN1; SMN2 (0.30) | CYP19A1 | |
| SCHEMBL8565776 | 0.69 | SMN1; SMN2 (0.30) | CYP19A1 | |
| SCHEMBL2150283 | 0.68 | ALDH1A1 (0.37) | CYP19A1EPHX2 | |
| SCHEMBL43433 | 0.68 | — | — | |
| SCHEMBL32667642 | 0.68 | ALDH1A1 (0.37) | CYP19A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183355-B2 | Method for the synthesis of oligonucleotide derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-05-22 | — | — | US | disclosed |
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | MSN, RNGTT, DCLRE1B | CYP19A1 4680/4885EPHX2 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.